FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to overcome such drug resistance. We es...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Koichi, Kawahara, Akihiko, Sonoda, Kahori, Nakashima, Kazutaka, Tashiro, Kousuke, Watari, Kosuke, Izumi, Hiroto, Kage, Masayoshi, Kuwano, Michihiko, Ono, Mayumi, Hoshino, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171601/
https://www.ncbi.nlm.nih.gov/pubmed/25115383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171601/
https://www.ncbi.nlm.nih.gov/pubmed/25115383

Ejemplares similares